Thorsten Waloschek/LinkedIn
Dec 21, 2025, 02:24
Thorsten Waloschek: New Study Highlights Preeclampsia Risk Stratification Benefits
Thorsten Waloschek, CEO of NeoPredics AG, shared a post on LinkedIn:
“This is an important signal for maternal health innovation in pregnancy.
A large new study shows that identifying women at higher risk of preeclampsia late in pregnancy, and acting on that risk with planned early-term birth, reduced term preeclampsia by around 30%.
Risk stratification, biomarkers, and structured decision-making during pregnancy can change outcomes – even without new drugs. This reinforces how much potential still sits in smarter diagnostics and data-driven pathways to protect mothers’ cardiovascular health during pregnancy.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Jan 12, 2026, 16:03New Insights Into Estrogen Receptor Alpha Regulation in the Endometrium – Fertility and Sterility
-
Jan 12, 2026, 15:37From Innovation to Practice: Standards for Embryo Diagnostic Trials – Fertility and Sterility
-
Jan 12, 2026, 14:47HFEA Updates Choose a Fertility Clinic Tool to Improve Success Reporting
-
Jan 12, 2026, 13:14Lucile Ferreux: Prenatal Cadmium Exposure and Its Long-Term Impact on Male Fertility
-
Jan 12, 2026, 13:11This Month’s Fertility and Sterility Unplugged Is Live – Fertility and Sterility
-
Jan 11, 2026, 10:02Hind Hanani: Understanding the Use of Antiphospholipid Syndrome Guidelines Worldwide
-
Jan 11, 2026, 09:58Exploring the Role of Antiphospholipid Antibodies in Severe Preeclampsia – RheumNow
-
Jan 11, 2026, 09:56Adrenal Involvement in Antiphospholipid Syndrome – ARP Rheumatology
-
Jan 11, 2026, 09:52Jamie Agunsday: Understanding Pregnancy-Related Deaths